20th KM , Electronics City, 560 100

For Immediate Release Bangalore, 11 October 2011

Biocon’s Q2 & H1 FY2012 Results Conference Call

at 3:00 pm IST on 20 October 2011

The management team of Limited will organize a conference call for analysts and investors on Thursday, 20 October 2011 at 3:00 pm IST following the announcement of financial results for the quarter and half year ended September 30, 2011. The call will be initiated with a brief management discussion on the Q2 & H1 FY2012 performance followed by an interactive Question & Answer session. Ms. Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon Limited, and other members of the senior management team will represent Biocon on the conference call.

Details of the conference call are as under:

Date: Thursday, 20 October 2011

Time: 3:00 pm IST

Dial-in Numbers:

Toll Free Number ( Only) 1800 200 7888 / 1800 102 1300 (India Toll Free numbers are accessible through all mobiles and landline services)

Direct Access Number (India Only) 1860 266 3376

Direct Access Number (National & International) +91 44 6688 0000 / +91 44 3994 7000

USA Toll Free 1800 974 0768 / 1866 380 1660 / 1877 387 0849

UK Toll Free 0808 101 6864 / 0808 101 7155 / 0800 635 0271

HK Toll Free 800 903 171 / 800 962 771

Replay Facility Available on 20 October 2011 – 26 October 2011 on the same dial-in numbers mentioned above The replay facility will begin after the call ends

The transcript of the conference call will be available within 7 working days of the call on the corporate website: www.biocon.com

- ENDS -

1

About Biocon

Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest biotechnology company by revenue. The Group, promoted by Ms Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on and research services. Biocon’s value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMEA acceptance. Biocon’s robust product offering includes the world’s first Pichia-based recombinant human insulin, INSUGEN® and India’s first indigenously produced monoclonal antibody BIOMAb-EGFR(TM).

For more information, visit www.biocon.com

For further information please contact: Jill Deviprasad Urvashi Butani Biocon Limited Citigate Dewe Rogerson Tel: +91 80 2808 2054 Tel: +91 22 6645 1219 Fax: +91 80 2852 3423 Fax: +91 22 6645 1213 Email: [email protected] Email: [email protected]

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management’s current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. There can be no assurance that future developments affecting Biocon and its subsidiaries / associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Biocon does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.

2